Polymorphisms in interleukin-10 gene according to mutations of NOD2/CARD15 gene and relation to phenotype in Spanish patients with Crohn’s disease

Table 2 Distribution of -1082G allele among different clinical subgroups of CD stratified by NOD2/CARD15 status

Phenotypic characteristics	Phenotype frequency of -1082 IL-10G(+)(n = 146) (%)	P	CARD15/NOD2 (+) -1082 IL-10 G(+)(n = 54) (%)	P	CARD15/NOD2 (-) -1082 IL-10 G(+)(n = 92) (%)	P
Sex
Men	67 (45.9)	0.67	24 (44.4)	0.77	43 (46.7)	0.45
Women	79 (54.1)		30 (55.5)		49 (53.3)
Age at diagnosis (yr)
A1, < 40	117 (80.1)		46 (85.2)	0.5	71 (77.2)	0.41
A2, ≥40	29 (19.9)	0.72	8 (14.8)		21 (22.8)
Family history	27 (18.5)	0.43	10 (18.5)	0.43	17 (18.5)	0.76
Smokers	64 (43.8)	0.55	24 (44.4)	0.86	40 (43.5)	0.65
Appendectomy	20 (13.7)	0.55	7 (12.9)	0.93	13 (14.1)	0.49
Tonsillectomy	22 (15.1)	0.11	5 (9.3)	0.66	17 (18.5)	0.19
Disease behavior
Nonstricturing, nonpenetrating (B1)	63 (43.2)	0.87	24 (44.4)	0.58	39 (42.4)	0.86
Stricturing (B2)	22 (15.1)		9 (16.7)		13 (14.1)
Penetrating (B3)	61 (41.8)		21 (38.9)		40 (43.5)
Location of disease
Terminal ileum (L1)	70 (47.9)	0.63	29 (53.7)	0.021	41 (44.6)	0.43
Colon (L2)	24 (16.4)		5 (9.3)		19 (20.7)
Ileocolon (L3)	47 (32.2)		19 (35.2)		28 (30.4)
Upper gastrointestinal (L4)	5 (3.4)		1 (1.9)		4 (4.3)
Perianal	39 (26.7)	0.3	11 (20.4)	1	28 (30.4)	0.3
Extraintestinal clinical manifestations
Cutaneous	27 (18.5)	0.56	9 (16.7)	0.29	18 (19.6)	0.93
Articular	49 (33.6)	0.69	16 (29.6)	0.83	33 (35.9)	0.83
Treatment
Surgical intervention	61 (41.8)	0.76	22 (40.7)	0.71	39 (42.4)	0.92
Infliximab	19 (13.0)	0.06	5 (9.3)	0.032	14 (15.2)	0.61
Immunosuppressants	63 (43.2)	0.81	25 (46.3)	0.72	38 (41.3)	0.63

¹ -1082G allele in NOD2/CARD15 mutation positive patients: ileocolonic location (P = 0.008, RR = 1.52, 95% CI = 1.21-1.91). ² -1082G allele in NOD2/CARD15 mutation positive patients: infliximab (P = 0.03, RR = 0.54, 95%CI = 0.27-1)